All articles
ComplianceSeptember 10, 2026·3 min read

Writing Recruitment Ads Your IRB Will Approve the First Time

IRBs reject recruitment ads over specific, predictable things. Here's the language that gets flagged, the skeleton of an approvable ad, and the submission habits that keep enrollment from stalling.

By Trialflow Team

Recruitment ad copy is one of the few site deliverables an IRB will reject over a single word. And because most sites submit ads late — after the site initiation visit, when enrollment pressure is already building — a rejection costs two to four weeks you didn't budget for. The fix is writing ads that are pre-cleared by design.

What IRBs are actually policing

IRB review of advertising isn't a style critique. Reviewers are checking that the ad doesn't function as an end-run around informed consent. In practice that means four things:

  • No promise of benefit. "New treatment that may help your migraines" implies efficacy that hasn't been established. "A research study of an investigational medication for migraine" does not.
  • No coercive emphasis on money. Payment can usually be mentioned, but it can't be the headline, bolded, or set in larger type. Many IRBs will approve "Compensation for time and travel may be provided" and reject "Earn up to $1,200."
  • Clear research framing. The word research or clinical trial should appear early, not buried in the footer. "Investigational" is your friend.
  • No claim of safety. "Safe and effective" and even "well-tolerated" are non-starters for an investigational product.

The elements that keep ads out of trouble

Most approved ads contain the same skeleton. Build your templates around it:

  1. A neutral statement that this is research
  2. The condition being studied, in plain language
  3. Two to four broad eligibility criteria — age range, diagnosis, maybe one exclusion
  4. What participation broadly involves (visits, duration)
  5. Site name, PI name where required, and contact information
  6. A brief compensation mention, if any, placed last

Avoid full eligibility lists. They date quickly, and every protocol amendment then forces a re-submission.

Where sites get tripped up

Social media captions and comments. The image gets approved; the caption doesn't. If you post approved creative and then write "lots of people have felt better on this!" in a reply, you've just distributed unapproved advertising. Give whoever manages your accounts a short list of approved response lines and a rule that anything else gets escalated.

Landing pages. Some IRBs treat the page a QR code leads to as part of the ad. Submit it. Screenshot it as approved and don't let marketing quietly A/B test the headline.

Translations. A back-translated Spanish version is a separate submission at most boards. Don't assume the English approval covers it.

Sponsor-supplied materials. Central IRB approval of a sponsor's ad doesn't always cover your site-specific version with your logo, address, and phone number. Confirm which pieces are locked and which are fill-in-the-blank.

A practical submission habit

Submit advertising with your initial packet, not later. Include every channel you might plausibly use in the next year — print flyer, radio script, social image with three caption variants, text-message invitation, landing page — even the ones you're unsure you'll run. Approval of an unused ad costs nothing. Getting an ad approved in month seven, when the sponsor is asking why you've enrolled two, costs a lot.

Keep a single tracked folder of approved versions with approval dates and expiration, and log every place each version has been posted. When a monitor asks where a specific flyer ran, you want an answer in under a minute.

Enrolling studies shouldn't be this hard

Trialflow gives research sites one platform for lead management, AI trial matching, and recruitment analytics.

Request a Demo